Simon Bruce is a seasoned executive in the biopharmaceutical industry, currently serving as Vice-President of Internal Medicine at ICON plc since May 2021, specializing in drug development services and consulting. With extensive experience in clinical development and strategic consulting, Simon has held key leadership positions at Kinexum Services LLC, Calcilytix, ADOCIA, Halozyme Therapeutics, Novartis, Amylin, Daiichi Sankyo, and Bristol-Myers Squibb. Notable achievements include leading the clinical development of an orphan drug for hypoparathyroidism and directing the advancement of significant diabetes therapies, including the DPP4 inhibitor Saxagliptin. Simon holds a BS in Neuroscience from Yale University and has training in Endocrinology from the National Institutes of Health.
This person is not in any teams
This person is not in any offices